Detectable ctDNA before complete surgical resection in patients with AJCC stage IIIB/C/D (high-risk stage III) with a BRAF, NRAS, or KIT mutant melanoma is an independent predictor of worse melanoma-specific survival (MSS) in patients receiving no systemic adjuvant therapy [122,136]. This evidence concerns the gene BRAF and melanoma.